In particular, the CSC phenotype in ovarian cancer was associated with elevated Notch3 expression, and in the case of chemoresistant tumors, the effect of combined administration of paclitaxel and GSI-I was more dependent on Notch3 than on Notch1 due to its relatively higher expression and was associated with decreased viability, migration, angiogenesis, and CSC pool [459,460]. This evidence concerns the gene NOTCH3 and ovarian carcinoma.